Iterum Therapeutics Reports Q3 2025 Financial Results

Iterum Therapeutics ( (ITRM) ) has released its Q3 earnings. Here is a breakdown of the information Iterum Therapeutics presented to its investors.

Iterum Therapeutics, a biopharmaceutical company, specializes in developing next-generation oral and IV antibiotics to combat infections caused by multi-drug resistant pathogens. The company, which operates in both community and hospital settings, recently reported its third-quarter 2025 financial results, highlighting the commercial launch of its novel antibiotic, ORLYNVAH™, in the United States.

In August 2025, Iterum launched ORLYNVAH™ for the treatment of uncomplicated urinary tract infections (uUTIs), marking a significant milestone as it is the first new branded treatment in this space in over 25 years. The company anticipates modest sales for 2025 due to its limited commercial infrastructure but expects net product sales to range between $5 million and $15 million in 2026, contingent on market uptake and payer coverage.

Key financial metrics from the third quarter of 2025 include net product revenues of $0.4 million from ORLYNVAH™ sales and a net loss of $9.0 million, compared to a $6.1 million loss in the same period in 2024. The increase in selling, general, and administrative expenses to $6.5 million from $1.8 million in the previous year reflects the costs associated with the commercialization of ORLYNVAH™. Additionally, Iterum has extended its cash runway into the second quarter of 2026, supported by its cash reserves and recent fundraising efforts.

Iterum’s strategic efforts include expanding its patent estate with new patents granted in China and Mexico, which secure its proprietary antibiotic combinations until 2041 and 2039, respectively. Looking ahead, Iterum remains focused on refining its market strategy and expanding the reach of ORLYNVAH™ as it navigates the evolving market dynamics in the antibiotic sector.